Supplementary Materials

Supplementary Material for:

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Eugenia R. Zanella, Francesco Galimi, Francesco Sassi, Giorgia Migliardi, Francesca Cottino, Simonetta M. Leto, Barbara Lupo, Jessica Erriquez, Claudio Isella, Paolo M. Comoglio, Enzo Medico, Sabine Tejpar, Eva Budinská, Livio Trusolino,* Andrea Bertotti*

*Corresponding author. E-mail: livio.trusolino{at}unito.it (L.T.); andrea.bertotti{at}unito.it (A.B.)

Published 28 January 2015, Sci. Transl. Med. 7, 272ra12 (2015)
DOI: 10.1126/scitranslmed.3010445

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Substitution of human stroma with mouse stroma after xenografting.
  • Fig. S2. Response to cetuximab and expression of EGFR family receptors and ligands.
  • Fig. S3. Expression changes of EGFR family receptors and ligands during cetuximab therapy.
  • Fig. S4. Identification of cases selected for combination therapy with cetuximab plus lapatinib.
  • Fig. S5. Effect of cetuximab plus lapatinib: cellularity and apoptosis.
  • Fig. S6. Response to cetuximab plus lapatinib and expression of EGFR family receptors and ligands.
  • Fig. S7. IGF1R phosphorylation in representative tumors from xenopatients.
  • Fig. S8. Response to cetuximab plus lapatinib and expression of EGFR family receptors and ligands in cases with low IGF2 overexpression.
  • Fig. S9. Frequency distribution of IGF2 expression in xenopatients.
  • Fig. S10. Expression of components of the IGF signaling network and association with IGF2 expression.
  • Fig. S11. Expression changes of IGF2 during cetuximab therapy.
  • Fig. S12. IGF1R phosphorylation in representative tumors from patients.
  • Fig. S13. Effect of IGF1R targeting in IGF2-overexpressing xenopatients.
  • References (4347)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Baseline microarray data from patients and xenopatients.
  • Table S2 (Microsoft Excel format). Microarray data after 72 hours and 6 weeks of cetuximab treatment.
  • Table S3 (Microsoft Excel format). Comparison between response to cetuximab monotherapy and response to cetuximab plus lapatinib.
  • Table S4 (Microsoft Excel format). IGF2 expression in 151 CRC cell lines.
  • Table S5 (Microsoft Excel format). List of primers used for gene expression and gene copy number analyses.

[Download Tables S1 to S5]